An adaptive biomarker strategy clinical trial design by unknown
ORAL PRESENTATION Open Access
An adaptive biomarker strategy clinical trial
design
James Wason1, Nigel Stallard2*, Janet Dunn3, Rob Stein4
From 2nd Clinical Trials Methodology Conference: Methodology Matters
Edinburgh, UK. 18-19 November 2013
The Biomarker Strategy Design has been proposed for
trials assessing the value of a biomarker in guiding treat-
ment in oncology. In such trials, patients are randomised
to a control arm, receiving the standard chemotherapy
treatment, or a biomarker-directed treatment arm, when
biomarker status is used to guide treatment. The rando-
mised groups are then compared, often using a non-
inferiority test to assess whether the biomarker-guided
therapy, limiting potentially toxic chemotherapy to a sub-
group of patients, is at least as effective as universal
chemotherapy.
Motivated by a current trial of biomarker guided adju-
vant chemotherapy in breast cancer, we consider an
adaptive version of this design in which two biomarkers
are assessed. The trial is conducted in two stages. In the
first stage, patients in the test-guided arm receive both a
standard and a new test, with the standard test guiding
treatment. An analysis comparing test results from this
stage is then used to choose the test to use in the
remainder of the trial, using the new test if the results
for the two tests are sufficiently similar.
We used the delta method to approximate the joint dis-
tribution of the results from the two stages, showing that
in practical situations the correlation between these is
near zero. First stage results can therefore be used to
adapt the trial without error rate inflation. We also show
that for an appropriately chosen decision rule there can be
considerable cost gains with only a small loss in power.
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